Ironwood Pharmaceuticals Inc. IRWD
Biotechnology: Pharmaceutical Preparations · IPO 2010 · data as of November 13, 2026
Ironwood Pharmaceuticals Inc. (IRWD) is a healthcare company listed in the US with a market value of about $800M. In the twelve months to September 30, 2026 it had revenue of $400M and net income of $150M, a net margin of 37.4%.
Its overall Stock Analiz score is 2.2 out of 5 (weak). The strongest part is value (4/5); the weakest is track record (1/5).
Key numbers: a P/E of 5.4, a price to free cash flow of 3.9, 5-year revenue growth of -5% a year, a 5-year average ROIC of 30%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 184% above the current price.
About Ironwood Pharmaceuticals
Ironwood Pharmaceuticals is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2010. Revenue went from $76M in 2014 to $296M in 2025, growth of about 13.1% a year. It was profitable in 6 of the last 10 years in our data. Its share count fell by 13% over three years (buybacks). It spends 32% of revenue on research and development.
Score: 2.2 / 5
Checks passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- Profit margin improving
- Strong R&D investment or growth above 20%
- 5-year average ROIC above 12%
- Positive free cash flow
Checks not passed
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year revenue growth above 8% a year
- Profitable 5 years in a row
- ROE above 15%
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $400M | $296M | $351M | $443M | $411M | $414M | $390M | $428M | $347M | $298M | $274M |
| Net income | $150M | $24M | $880000 | -$1.0B | $175M | $528M | $106M | $22M | -$282M | -$117M | -$82M |
| Free cash flow | $205M | $127M | $103M | $183M | $274M | $262M | $167M | $4M | -$71M | -$104M | -$30M |
| EPS (diluted) | $0.90 | $0.15 | $0.01 | $-6.45 | $0.96 | $3.21 | $0.66 | $0.14 | $-1.85 | $-0.78 | $-0.56 |
| Net margin | 37.4% | 8.1% | 0.2% | -226.4% | 42.6% | 127.7% | 27.3% | 5.0% | -81.5% | -39.2% | -29.8% |
| ROIC | — | 57.1% | — | — | 16.2% | 17.0% | 27.0% | 35.5% | -323.2% | -7.7% | -13.6% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 4 analysts is $6.17, 28% above the current price; targets range from $3.70 to $10.00; the consensus rating is “Buy”; expected EPS is $1.30 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Ironwood Pharmaceuticals’s P/E ratio?
About 5.4, based on the last twelve months of diluted earnings per share (forward P/E about 3.3).
Is Ironwood Pharmaceuticals stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 184% above the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Ironwood Pharmaceuticals pay a dividend?
Not currently.
Is Ironwood Pharmaceuticals a good stock to buy?
We do not give buy or sell advice. Ironwood Pharmaceuticals scores 2.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.